CurrentRheuma
Get Weekly

CurrentRheuma coverage · page 13 of 15

Annals of the Rheumatic Diseases

Briefs 481–520 of 596 CurrentRheuma has covered from this journal, newest publication first

Latest from Annals of the Rheumatic Diseases

All coverage, newest first

  1. Ann Rheum Dis

    Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

    Randomized controlled trialSpondyloarthritis & PsA

  2. Ann Rheum Dis

    HLA-B27, axial spondyloarthritis and survival

    Cohort studySpondyloarthritis & PsA

  3. Ann Rheum Dis

    Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism

    Cohort studyAutoinflammatory & rare

  4. Ann Rheum Dis

    Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial

    Randomized controlled trialGout & crystals

  5. Ann Rheum Dis

    2023 ACR/EULAR antiphospholipid syndrome classification criteria

    Diagnostic or prognostic studyLupus & APS

  6. Ann Rheum Dis

    Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

    Randomized controlled trialRA

  7. Ann Rheum Dis

    Evaluating the causal effect of circulating proteome on the risk of osteoarthritis-related traits

    Research articleOsteoarthritis

  8. Ann Rheum Dis

    Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups

    Mechanistic studySystemic sclerosis

  9. Ann Rheum Dis

    Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus

    Mechanistic studyLupus & APS

  10. Ann Rheum Dis

    Benralizumab for eosinophilic granulomatosis with polyangiitis

    Cohort studyVasculitis & PMR

  11. Ann Rheum Dis

    Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial

    Secondary analysisRA

  12. Ann Rheum Dis

    Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis

    Mechanistic studySpondyloarthritis & PsA

  13. Ann Rheum Dis

    Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis

    Mechanistic studyRA

  14. Ann Rheum Dis

    The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Diagnostic or prognostic studyGout & crystals

  15. Ann Rheum Dis

    Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study

    Cohort studyRA

  16. Ann Rheum Dis

    SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy

    Mechanistic studyLupus & APS

  17. Ann Rheum Dis

    The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

    Guideline or statementAutoinflammatory & rare

  18. Ann Rheum Dis

    Single-cell transcriptome analysis profiles cellular and molecular alterations in submandibular gland and blood in IgG4-related disease

    Mechanistic studyAutoinflammatory & rare

  19. Ann Rheum Dis

    Multimodal repertoire analysis unveils B cell biology in immune-mediated diseases

    Mechanistic studyLupus & APS

  20. Ann Rheum Dis

    Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis

    Cohort studyRA

  21. Ann Rheum Dis

    Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands

    Research articleRA

  22. Ann Rheum Dis

    Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

    Randomized controlled trialRA

  23. Ann Rheum Dis

    Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study

    Cohort studyAcross diseases

  24. Ann Rheum Dis

    Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis

    Mechanistic studySystemic sclerosis

  25. Ann Rheum Dis

    Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020

    Cohort studyVasculitis & PMR

  26. Ann Rheum Dis

    Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares

    Cohort studyLupus & APS

  27. Ann Rheum Dis

    Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis

    Mechanistic studyRA

  28. Ann Rheum Dis

    Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database

    Cohort studyAcross diseases

  29. Ann Rheum Dis

    Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

    Secondary analysisRA

  30. Ann Rheum Dis

    EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis

    Guideline or statementSpondyloarthritis & PsA

  31. Ann Rheum Dis

    Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)

    Cohort studyAcross diseases

  32. Ann Rheum Dis

    Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort

    Cohort studyOsteoarthritis

  33. Ann Rheum Dis

    JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

    Meta-analysisAcross diseases

  34. Ann Rheum Dis

    Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry

    Cross-sectional studyRA

  35. Ann Rheum Dis

    Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial

    Randomized controlled trialRA

  36. Ann Rheum Dis

    Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients

    Cohort studyVasculitis & PMR

  37. Ann Rheum Dis

    Points to consider: EULAR–UEMS standards for the training of European rheumatologists

    Guideline or statement

  38. Ann Rheum Dis

    Autoantibodies identify primary Sjögren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B

    Case-control studySjögren's & overlap

  39. Ann Rheum Dis

    Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults

    Cohort studyAutoinflammatory & rare

  40. Ann Rheum Dis

    Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies

    Randomized controlled trial

All 596 Briefs in ExploreShowing Briefs 481–520 of 596, newest first